Clinical Role of Testosterone and Dihydrotestosterone and Which of Them Should be Inhibited in COVID-19 Patients - A Double-edged Sword?

Clinical Role of Testosterone and Dihydrotestosterone and which of them should be inhibited in COVID-19 patients - A double-edged sword?

COVID-19 attacks and affects Males significantly more than females [1], [2]. Males with COVID-19 are reported to die at twice the rate of females when they come infected with the virus [3]. The upregulation of TMPRSS2 by androgens could explain the increased susceptibility to COVID-19 in men.Contrary to expected, as a study demonstrated that The expression level of TMPRSS2 increased 6-fold in androgen stimulated LNCaP cells, relative to androgen-deprived cells[4]. But, surprisingly, low levels of testosterone led to the over expression and upregulation of ACE2 and TMPRSS2 receptors, facilitating SARS-CoV-1 entry into the alveolar cells, and deregulating a lung-protective pathway [5].According to literature Dihydrotestosterone is many times more potent than testosterone, and many of the effects that testosterone has in the body only happen after it is converted to dihydrotestosterone [6]. Therefore, we hypothesis that testosterone has better effect than dihydrotestosterone in case of COVID-19, because a study found that DHT significantly induced the expression of TMPRSS2 [7]. And at the same time , decreased testosterone levels in critically diseased males harmfully affect pulmonary endothelial cell functioning, impair the ability to clear the virus , promote systemic . Obesity among males, promote defective immune response, , and also generates more pro-inflammatory cytokines important in cell signaling, emanating in increased, severe disease, worst outcome and vulnerability. Insufficient serum testosterone level is a poor prognostic indicator for patients infected with COVID-19 by downregulation pulmonary protective pathways [5], [8]. On the contrary, high testosterone levels can lead to complication of thrombosis which is also one of the serious manifestations in COVID-19 patients[9]. Thereby we hypothesize that decreased testosterone levels in men have a direct relation with the severity of infection and a worse outcome in COVID-19. In this case we should found an appropriate treatment that induces testosterone level to introduce its protective effect and up regulate pulmonary protective pathways and at the same time protect against thrombosis and works to reduce the impact of dihydrotestosterone on lung cells preventing up regulation of TMPRSS2, Her we shed new light on the appropriate treatment can overcome the challenges that face testosterone therapy in the era of COVID-19 After searching MEDLINE , PubMed, , Google Scholar, preprints and Controlled Trials until September , 2020 we found that the appropriate treatment in this case is aerosolized 13 cis retinoic acid in combination with testosterone therapy, as more than one study found that 13 cis retinoic acid reversibly and potentially inhibit the effect of dihydrotestosterone on different targeted cells. In addition its impact on thrombin.

Study Overview

• Status: Unknown
• Conditions: Covid19
• Intervention / Treatment: Combination product: Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone; Drug: The standard therapy

Detailed Description

The study is a randomized interventional comparative Phase IIII trial. 1000 adult male and female patients with positive COVID-19 diagnosis and fulfilling the below outlined inclusion criteria will be enrolled into the study.

After searching PubMed, MEDLINE, Google Scholar, preprints and Controlled Trials until September , 2020 we found that the best and appropriate drug which can be combined with testosterone replacement therapy is aerosolized 13 cis retinoic acid owing to its impact on DHT and thrombin in addition it can be given in the form of aerosol for targeting pulmonary cells with minimal systemic side effects . As previous study found that testosterone therapy (TTh) administration using both topical and injectable formulations yielded transient and concomitant rises in both DHT and T, with higher Hct elevations in men with higher DHT and T levels[38]. As Testosterone is converted to DHT by the action of 5 alpha-reductase enzyme at these target tissues.[39]. DHT is a potent activator of TMPRSS2[31,4] and this will be followed by the activation of COVID-2019 spike protein to bind to its ACE2 receptors in lung which in turn makes it more vulnerable to covid-19. A study demonstrated that 13- cis -Retinoic acid competitively and reversibly inhibits dihydrotestosterone.[40] on contrary to other selective inhibitor of serum DHT which led to sexual adverse effects because it usually given systemically which increases the chance of systemic serious side effects . But 13- cis -Retinoic acid will be given in the form of aerosol to avoid these systemic side effects. Therefore, we suggest that 13- cis -Retinoic acid will downregulate TMPRSS2 expression thorough temporary preventing the effect of dihydrotestosterone (DHT) on the activation of TMPRSS2 gene expression. Furthermore, 13- cis -Retinoic acid Found to exert potential effect on thrombin as high testosterone levels can lead to thrombosis which is also one of the fatal manifestations in COVID-19 patients .A study in vitro found that Retinoic acid showed the highest inhibition of both the forms of thrombin [41].

Moreover, we hypothesize that any drug which downregulates TMPRSS2 expression through targeting AR, AR co-regulatory factors, or AR downstream transcription factors might be potentially effective against COVID-19 and is worth investigating under a clinical trial.

• Study Type: Interventional
• Enrollment (Anticipated): 1000
• Phase: Phase 4

Contacts and Locations

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 68 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Adult SARI patients with 2019-ncov infection confirmed by PCR; Absolute value of lymphocytes < 0. 6x 109/L; Severe respiratory failure within 48 hours and requires admission to ICU. (severe respiratory failure was defined as PaO2/FiO2 < 200 mmHg and was supported by positive pressure mechanical ventilation (including non-invasive and invasive mechanical ventilation, PEEP>=5cmH2O))

Exclusion Criteria:

Age < 18 Pregnant Allergic to experimental drugs and patients have the following conditions:

• Hypercholesterolemia
• Hypertriglyceridemia
• Liver disease
• Renal disease
• Sjögren syndrome
• Pregnancy
• Lactation
• Depressive disorder
• Body mass index less than 18 points or higher than 25 points
• Contraindications for hormonal contraception or intrauterine device.
• Autoimmune diseases A history of organ, bone marrow or hematopoietic stem cell transplantation
• Patients receiving anti-hcv treatment
• Permanent blindness in one eye
• History of iritis, endophthalmitis, scleral inflammation or retinitis 15-90 days of retinal detachment or eye surgery
• Known malignant disease, PSA > 3 ug/L, Nycturia > 3 times
• The competent physician considered it inappropriate to participate in the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone; The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days; The infected patients will be treated with a single dose of testosterone (0.1, 0.2, or 0.3 mg) by inhalation for 14 days	Combination product: Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone; The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days; The infected patients will be treated with a single dose of testosterone (0.1, 0.2, or 0.3 mg) by inhalation for 14 days
Sham Comparator: The standard therapy; infected patients will receive the standard therapy for COVID-19 for 14 days	Drug: The standard therapy; infected patients will receive the standard therapy for COVID-19 for 14 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
lung injury score	Proportion of lung injury score decreased or increased after treatment	at 7and 14 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Absolute lymphocyte counts	lymphocyte counts	at 7and 14 days
Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon	Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon	at 7and 14 days
Serum level of COVID19 RNA	Serum level of COVID19 RNA	at 7and 14 days
Angiotensin 1-7 (Ang 1-7) changes over time	Angiotensin 1-7 (Ang 1-7) changes over time	at 7and 14 days
Angiotensin 1-5 (Ang 1-5) changes over time	Angiotensin 1-5 (Ang 1-5) changes over time	at 7and 14 days
Renin changes over time	Renin changes over time	at 7and 14 days
Aldosterone changes over time	Aldosterone changes over time	at day 7 and 14
Angiotensin-converting enzyme (ACE) changes over time	Angiotensin-converting enzyme (ACE) changes over time	at day 7 and 14
Frequency of adverse events and severe adverse events	Frequency of adverse events and severe adverse events	at day 7 and 14
Transe membrane protease ,serine II (TMPRSS2) changes over time	Transe membrane protease ,serine II (TMPRSS2) changes over time	day 7 and 14
Testosterone levels changes over time	Testosterone levels changes over time	day 7 and 14
Dihydrotestosterone(DHT) levels changes over time	Dihydrotestosterone(DHT) levels changes over time	day 7 and 14
Cholesterol levels changes over time	Cholesterol levels changes over time	day 7 and 14
Thrombin time (TT)	Thrombin time (TT)	day 7 and 14

Collaborators and Investigators

• Sponsor: Kafrelsheikh University

Study record dates

Study Major Dates

• Study Start (Anticipated): November 1, 2020
• Primary Completion (Anticipated): December 1, 2020
• Study Completion (Anticipated): December 1, 2021

Study Registration Dates

• First Submitted: November 8, 2020
• First Submitted That Met QC Criteria: November 9, 2020
• First Posted (Actual): November 10, 2020

Study Record Updates

• Last Update Posted (Actual): November 10, 2020
• Last Update Submitted That Met QC Criteria: November 9, 2020
• Last Verified: November 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19; Physiological Effects of Drugs; Antineoplastic Agents; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Dermatologic Agents; Keratolytic Agents; Androgens; Testosterone; Tretinoin; Isotretinoin
• Other Study ID Numbers: SARS -2

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No